Long-term use of statins reduces the risk of hospitalization fordementia

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 171-176

  Corrao, Giovanni ^a   Ibrahim, Buthaina ^a   Nicotra, Federica ^a   Zambon, Antonella ^a   Merlino, Luca ^b   Pasini, Thea Scognamiglio ^a   Catapano, Alberico L ^c,d   Mancia, Giuseppe ^a,e  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Operative Unit of Territorial Health Services   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Alzheimer's disease; Dementia; Healthcare Utilization Database; Lipid lowering agents; Monte Carlo sensitivity analysis; Record linkage; Rule out sensitivity analysis; Statins; Unmeasured confounders

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ALZHEIMER'S DISEASE; DEMENTIA; HEALTHCARE UTILIZATION DATABASE; LIPID-LOWERING AGENTS; MONTE-CARLO SENSITIVITY ANALYSIS; RECORD LINKAGE; RULE-OUT SENSITIVITY ANALYSIS; STATINS; UNMEASURED CONFOUNDERS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DEMENTIA; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; RISK; SIMVASTATIN; TIME FACTORS;

EID: 84884537112     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.009     Document Type: Article

References (44)

1. Breteler M.M., Claus J.J., Grobbee D.E., Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994, 308:1604-1608.
2. Newman A.B., Fitzpatrick A.L., Lopez O., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. JAm Geriatr Soc 2005, 53:1101-1107.
3. Catapano A.L., Reiner Z., De Backer G., European Society of Cardiology (ESC), European Atherosclerosis Society (EAS), et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
4. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009, 338:b2376.
5. Yanuck D., Mihos C.G., Santana O. Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review. Int J Neurosci 2012, 122:619-629.
6. Giubilei F., D'Antona R., Antonini R., Lenzi G.L., Ricci G., Fieschi C. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand 1990, 81:84-86.
7. Etminan M., Gill S., Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003, 6:726-730.
8. Beydoun M.A., Beason-Held L.L., Kitner-Trolo M.H., et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. JEpidemiol Community Health 2011, 65:949-957.
9. Arvanitakis Z., Schneider J.A., Wilson R.S., et al. Statins, incident Alzheimer's disease, change in cognitive function, and neuropathology. Neurology 2008, 70:1795-1802.
10. Group HPSC MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
11. Shepherd J., Blauw G.J., Murphy M.B., PROSPER Study Group, PROspective Study of Pravastatin in the Elderly at Risk, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
12. Corrao G., Cesana G., Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. Biomed Stat Clin Epidemiol 2008, 2:117-125.
13. Parikh N.M., Morgan R.O., Kunik M.E., et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry 2011, 26:749-757.
14. Helin-Salmivaara A., Lavikainen P., Korhonen M.J., et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther 2008, 30:2228-2240.
15. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008, 168:329-335.
16. Charlson M.E., Charlson R.E., Peterson J.C., Marinopoulos S.S., Briggs W.M., Hollenberg J.P. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. JClin Epidemiol 2008, 61:1234-1240.
17. Breslow N.E., Day N.E. The analysis of case-control studies. Statistical methods in cancer research 1980, Vol. I. IARC Scientific Publications N° 32, International Agency for Research on Cancer, Lyon.
18. Greenland S. Sensitivity analysis, Monte-Carlo risk analysis and Bayesian uncertainty assessment. Risk Anal 2001, 21:579-583.
19. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012, 307:1302-1309.
20. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's disease and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009, 28:75-80.
21. Corrao G., Nicotra F., Parodi A., et al. External adjustment for unmeasured confounders improved drug-outcome association estimates based on health care utilization data. JClin Epidemiol 2012, 65:1190-1199.
22. Byers A.L., Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011, 7:323-331.
23. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 2000, 160:2101-2107.
24. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006, 15:291-303.
25. Otte C., Zhao S., Whooley M.A. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. JClin Psychiatry 2012, 73:610-615.
26. Zamrini E., McGwin G., Roseman J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004, 23:94-98.
27. Cramer C., Haan M.N., Galea S., Langa K.M., Kalbfleisch J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71:344-350.
28. Gresser U., Gathof B.S. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004, 9:1-17.
29. Wolozin B., Wang S.W., Li N.-C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007, 5:20.
30. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. JNeurol Neurosurg Psychiatry 2009, 80:13-17.
31. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol and statins in Alzheimer's disease. Arch Neurol 2011, 68:1385-1392.
32. Fleminger S., Oliver D.L., Lovestone S., Rabe-Hesketh S., Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. JNeurol Neurosurg Psychiatry 2003, 74:857-862.
33. Hsu C.C., Wahlqvist M.L., Lee M.S., Tsai H.N. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. JAlzheimers Dis 2011, 24:485-493.
34. Chang-Quan H., Hui W., Chao-Min W., et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011, 65:1295-1305.
35. Strom B.L. Overview of automated databases in pharmacoepidemiology. Pharmacoepidemiology 2000, 219-222. Wiley, Chichester, UK. 3rd ed. B.L. Strom (Ed.).
36. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158:915-920.
37. Stürmer T., Funk M.J., Poole C., Brookhart M.A. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 2011, 22:298-301.
38. Halpern M.T., Khan Z.M., Schmier J.K., et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006, 47:1039-1048.
39. Schneeweiss S., Avorn J. Areview of uses of health care utilization databases for epidemiologic research on therapeutics. JClin Epidemiol 2005, 58:323-337.
40. Kelsey J.L., Whittemore A.S., Evans A.S., Thompson W.D. Methods in observational epidemiology 1996, Oxford University Press, New York. 2nd ed.
41. Taylor D.H., Fillenbaum G.G., Ezell M.E. The accuracy of medicare claims data in identifying Alzheimer's disease. JClin Epidemiol 2002, 55:929-937.
42. Román G. Diagnosis of vascular dementia and Alzheimer's disease. Int J Clin Pract Suppl 2001, 120:9-13.
43. Cohen C.I., Araujo L., Guerrier R., Henry K.A. 'Mixed dementia': adequate or antiquated? A critical review. Am J Geriatr Psychiatry 1997, 5:279-283.
44. Willey J.Z., Elkind M.S. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010, 67:1062-1067.